Literature DB >> 30572726

Nanotheranostics, a future remedy of neurological disorders.

Manju Sharma1, Taru Dube1, Sonika Chibh1, Avneet Kour1, Jibanananda Mishra2, Jiban Jyoti Panda1.   

Abstract

INTRODUCTION: Effective therapy of various neurological disorders is hindered on account of the failure of various therapeutics crossing blood-brain-barrier (BBB). Nanotheranostics has emerged as a cutting-edge unconventional theranostic nanomedicine, capable of realizing accurate diagnosis together with effective and targeted delivery of therapeutics across BBB to the unhealthy regions of the brain for potential clinical success. AREAS COVERED: We have tried to review the current status of nanotheranostic based approaches followed to manage neurological disorders. The focus has been majorly laid on to explore various theranostic nanoparticles and their application potential towards image-guided neurotherapies. Additionally, the usefulness of exceptional diagnostic, imaging techniques including magnetic resonance imaging and fluorescence imaging are being discussed by highlighting their promising opportunities in the detection, diagnosis, and treatment of the neurological disorders. EXPERT OPINION: Inimitable diagnostic and therapeutic potential of nanotheranostics have accomplished the aim of personalized therapies by governing the therapeutic efficacy of the system along with facilitating patient pre-selection grounded on non-invasive imaging, thereby predicting the responses of patients to nanomedicine treatments. While these accomplishments are encouraging, they are still the minority and demands for a continuous effort to improve sensitivity and precision in screening/diagnosis along with improving therapeutic efficacy in various neural disorders.

Entities:  

Keywords:  BBB; contrast agent; image-guided therapy; nanoparticles; nanotheranostics; neurological disorders; targeted drug delivery

Mesh:

Year:  2019        PMID: 30572726     DOI: 10.1080/17425247.2019.1562443

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  7 in total

1.  Exploring the Interactions of Ruthenium (II) Carbosilane Metallodendrimers and Precursors with Model Cell Membranes through a Dual Spin-Label Spin-Probe Technique Using EPR.

Authors:  Riccardo Carloni; Natalia Sanz Del Olmo; Paula Ortega; Alberto Fattori; Rafael Gómez; Maria Francesca Ottaviani; Sandra García-Gallego; Michela Cangiotti; F Javier de la Mata
Journal:  Biomolecules       Date:  2019-09-27

2.  An In Vivo Study of a Rat Fluid-Percussion-Induced Traumatic Brain Injury Model with [11C]PBR28 and [18F]flumazenil PET Imaging.

Authors:  Krishna Kanta Ghosh; Parasuraman Padmanabhan; Chang-Tong Yang; Zhimin Wang; Mathangi Palanivel; Kian Chye Ng; Jia Lu; Jan Carlstedt-Duke; Christer Halldin; Balázs Gulyás
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

Review 3.  Nanomaterials as Novel Cardiovascular Theranostics.

Authors:  Rajasekharreddy Pala; Subhaswaraj Pattnaik; Siddhardha Busi; Surya M Nauli
Journal:  Pharmaceutics       Date:  2021-03-07       Impact factor: 6.321

Review 4.  Inorganic Nanomaterial for Biomedical Imaging of Brain Diseases.

Authors:  Wenxian Du; Lingling Zhou; Qiang Zhang; Xin Liu; Xiaoer Wei; Yuehua Li
Journal:  Molecules       Date:  2021-12-03       Impact factor: 4.411

Review 5.  In Vitro Models of the Blood-Cerebrospinal Fluid Barrier and Their Applications in the Development and Research of (Neuro)Pharmaceuticals.

Authors:  Fatemeh Dabbagh; Horst Schroten; Christian Schwerk
Journal:  Pharmaceutics       Date:  2022-08-18       Impact factor: 6.525

Review 6.  Nanotheranostics and its role in diagnosis, treatment and prevention of COVID-19.

Authors:  Lipsa Leena Panigrahi; Banishree Sahoo; Manoranjan Arakha
Journal:  Front Mater Sci       Date:  2022-08-03       Impact factor: 2.612

Review 7.  Smart magnetic resonance imaging-based theranostics for cancer.

Authors:  Beatriz Brito; Thomas W Price; Juan Gallo; Manuel Bañobre-López; Graeme J Stasiuk
Journal:  Theranostics       Date:  2021-08-07       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.